This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

ASPPH proudly joined public health and medical leaders for a Congressional Briefing on the Hepatitis C Elimination Imperative ...

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

This article provides a comprehensive look at how healthcare settings can prevent the transmission of bloodborne pathogens ...

The HIV/HBV/HCV test kits market plays a vital role in the global fight against infectious diseases. These diagnostic tools are crucial for early detection and effective treatment of HIV, hepatitis B ...

aDepartment of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan bDepartment of Internal Medicine, National Taiwan University ...

Some forms of the virus can become chronic and lead to life-threatening complications. Other symptoms resolve without any specific treatment. The most common types of hepatitis are HAV and HCV. HAV is ...

Discover a study where figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in ...

If you’ve been told you have the hepatitis C virus (HCV), you should know you’re not alone. A silent epidemic, chronic hepatitis C affects an estimated 2.4 million Americans, according to the ...